We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant ("MDR”) bacterial infections with high unmet need. Our pipeline consists of three mid to late-stage clinical assets. Tebipenem HBr is in Phase 3 development, with the potential to be the first broad-spectrum oral carbapenem to treat complicated urinary tract infections ("cUTIs”) including acute pyelonephritis, caused by certain microorganisms, in adult patients. SPR206 is a Phase 2 ready IV-administered antibiotic being developed as an innovative option to treat MDR Gram-negative bacterial infections in the hospital setting. SPR720, the development of which was recently suspended, is a Phase 2 investigational oral agent for the first-line treatment of nontuberculous mycobacterial ("NTM”) pulmonary disease, a rare disease. As previously disclosed, following the SPR720 program suspension, we are evaluating other potential paths forward as the remaining data are collected and analyzed.
Company Details
- Employees
- 47
- Founded
- -
- Address
- 675 Massachusetts Ave,
- Phone
- +1 857 242 1600
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- sperotherapeutics.com
- HQ
- Cambridge, MA
Spero Therapeutics Questions
Spero Therapeutics's helpline number is +1 857 242 1600
Spero Therapeutics's website is sperotherapeutics.com
Spero Therapeutics's LinkedIn profile is https://www.linkedin.com/company/spero-therapeutics
Spero Therapeutics has
47 employees.
View email and phone details for 47
employees at Spero Therapeutics.
Spero Therapeutics's industry is
Biotechnology Research
Spero Therapeutics's top competitors are
Beam Therapeutics,
Sarepta Therapeutics,
Sage Therapeutics,
Intellia Therapeutics, Inc.,
Nimbus Therapeutics,
Strand Therapeutics,
Bluerock Therapeutics,
Tessera Therapeutics,
Verve Therapeutics,
Seres Therapeutics.
Spero Therapeutics's categories are Biotechnology Research
Spero Therapeutics's founding year is 2013
